From: Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer
Response
Symptom Improvement
No.
%
CR+PR
1+5
18.2
SD
12
36.3
PD
0
Total
18
54.5